Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection

Frank Romanelli, Kerry Empey, Claire Pomeroy

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

This retrospective chart review was conducted in an outpatient human immunodeficiency virus (HIV) clinic to determine if macrocytosis can be used as a clinical indicator of zidovudine adherence in HIV-infected outpatients. This study included 71 HIV-positive patients who were taking zidovudine and 93 HIV-positive controls who were not taking zidovudine, for 8 weeks or longer. One control and 16 subjects were excluded secondary to insufficient laboratory data or preexistence of other macrocytosis-inducing etiologies. The incidence of macrocytosis (mean corpuscular volume [MCV] ≥ 100 fL) was significantly different among subjects and controls: 78% versus 32.6% (p < 0.001), respectively. Adherence (determined by documentation from a physician/pharmacist) was assessed among subjects for whom zidovudine was prescribed, comparing those with and without macrocytosis. Adherence was observed in 77% and 18% of the macrocytosis-positive and macrocytosis-negative subjects, respectively (p < 0.001). Macrocytosis was also observed in patients receiving stavudine (another thymidine analogue, in the class of nucleoside reverse transcriptase inhibitors). Twentyseven of the 41 patients for whom stavudine was prescribed developed macrocytosis (65.8%). These results indicate that macrocytosis may be useful in assessing adherence to zidovudine-containing antiretroviral regimens and may also have a role in assessing stavudine adherence.

Original languageEnglish (US)
Pages (from-to)405-411
Number of pages7
JournalAIDS Patient Care and STDs
Volume16
Issue number9
DOIs
StatePublished - Sep 1 2002
Externally publishedYes

Fingerprint

Medication Adherence
Zidovudine
Virus Diseases
Stavudine
HIV
Outpatients
Reverse Transcriptase Inhibitors
Erythrocyte Indices
Nucleosides
Pharmacists
Documentation
Thymidine
Physicians
Incidence

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Leadership and Management
  • Nursing(all)

Cite this

Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection. / Romanelli, Frank; Empey, Kerry; Pomeroy, Claire.

In: AIDS Patient Care and STDs, Vol. 16, No. 9, 01.09.2002, p. 405-411.

Research output: Contribution to journalArticle

Romanelli, Frank ; Empey, Kerry ; Pomeroy, Claire. / Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection. In: AIDS Patient Care and STDs. 2002 ; Vol. 16, No. 9. pp. 405-411.
@article{4aae3307dc7c4ede94291360541c585e,
title = "Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection",
abstract = "This retrospective chart review was conducted in an outpatient human immunodeficiency virus (HIV) clinic to determine if macrocytosis can be used as a clinical indicator of zidovudine adherence in HIV-infected outpatients. This study included 71 HIV-positive patients who were taking zidovudine and 93 HIV-positive controls who were not taking zidovudine, for 8 weeks or longer. One control and 16 subjects were excluded secondary to insufficient laboratory data or preexistence of other macrocytosis-inducing etiologies. The incidence of macrocytosis (mean corpuscular volume [MCV] ≥ 100 fL) was significantly different among subjects and controls: 78{\%} versus 32.6{\%} (p < 0.001), respectively. Adherence (determined by documentation from a physician/pharmacist) was assessed among subjects for whom zidovudine was prescribed, comparing those with and without macrocytosis. Adherence was observed in 77{\%} and 18{\%} of the macrocytosis-positive and macrocytosis-negative subjects, respectively (p < 0.001). Macrocytosis was also observed in patients receiving stavudine (another thymidine analogue, in the class of nucleoside reverse transcriptase inhibitors). Twentyseven of the 41 patients for whom stavudine was prescribed developed macrocytosis (65.8{\%}). These results indicate that macrocytosis may be useful in assessing adherence to zidovudine-containing antiretroviral regimens and may also have a role in assessing stavudine adherence.",
author = "Frank Romanelli and Kerry Empey and Claire Pomeroy",
year = "2002",
month = "9",
day = "1",
doi = "10.1089/108729102760330245",
language = "English (US)",
volume = "16",
pages = "405--411",
journal = "AIDS Patient Care and STDs",
issn = "1087-2914",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection

AU - Romanelli, Frank

AU - Empey, Kerry

AU - Pomeroy, Claire

PY - 2002/9/1

Y1 - 2002/9/1

N2 - This retrospective chart review was conducted in an outpatient human immunodeficiency virus (HIV) clinic to determine if macrocytosis can be used as a clinical indicator of zidovudine adherence in HIV-infected outpatients. This study included 71 HIV-positive patients who were taking zidovudine and 93 HIV-positive controls who were not taking zidovudine, for 8 weeks or longer. One control and 16 subjects were excluded secondary to insufficient laboratory data or preexistence of other macrocytosis-inducing etiologies. The incidence of macrocytosis (mean corpuscular volume [MCV] ≥ 100 fL) was significantly different among subjects and controls: 78% versus 32.6% (p < 0.001), respectively. Adherence (determined by documentation from a physician/pharmacist) was assessed among subjects for whom zidovudine was prescribed, comparing those with and without macrocytosis. Adherence was observed in 77% and 18% of the macrocytosis-positive and macrocytosis-negative subjects, respectively (p < 0.001). Macrocytosis was also observed in patients receiving stavudine (another thymidine analogue, in the class of nucleoside reverse transcriptase inhibitors). Twentyseven of the 41 patients for whom stavudine was prescribed developed macrocytosis (65.8%). These results indicate that macrocytosis may be useful in assessing adherence to zidovudine-containing antiretroviral regimens and may also have a role in assessing stavudine adherence.

AB - This retrospective chart review was conducted in an outpatient human immunodeficiency virus (HIV) clinic to determine if macrocytosis can be used as a clinical indicator of zidovudine adherence in HIV-infected outpatients. This study included 71 HIV-positive patients who were taking zidovudine and 93 HIV-positive controls who were not taking zidovudine, for 8 weeks or longer. One control and 16 subjects were excluded secondary to insufficient laboratory data or preexistence of other macrocytosis-inducing etiologies. The incidence of macrocytosis (mean corpuscular volume [MCV] ≥ 100 fL) was significantly different among subjects and controls: 78% versus 32.6% (p < 0.001), respectively. Adherence (determined by documentation from a physician/pharmacist) was assessed among subjects for whom zidovudine was prescribed, comparing those with and without macrocytosis. Adherence was observed in 77% and 18% of the macrocytosis-positive and macrocytosis-negative subjects, respectively (p < 0.001). Macrocytosis was also observed in patients receiving stavudine (another thymidine analogue, in the class of nucleoside reverse transcriptase inhibitors). Twentyseven of the 41 patients for whom stavudine was prescribed developed macrocytosis (65.8%). These results indicate that macrocytosis may be useful in assessing adherence to zidovudine-containing antiretroviral regimens and may also have a role in assessing stavudine adherence.

UR - http://www.scopus.com/inward/record.url?scp=0036742740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036742740&partnerID=8YFLogxK

U2 - 10.1089/108729102760330245

DO - 10.1089/108729102760330245

M3 - Article

C2 - 12396692

AN - SCOPUS:0036742740

VL - 16

SP - 405

EP - 411

JO - AIDS Patient Care and STDs

JF - AIDS Patient Care and STDs

SN - 1087-2914

IS - 9

ER -